BMS says it will take an additional year to meet its target for new drugs.

Published Date: 28 Oct 2023

In light of the longer than anticipated sales ramp-up of medications like the multiple sclerosis drug Zeposia and the psoriasis treatment Sotyktu, Bristol Myers Squibb on Thursday pushed back by a year the timeline for its new-product portfolio to reach $10 billion in revenue.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

2.

The main subject is associated with suicide in the United States.

3.

Alkem introduces cetuximab under the trade name Cetuxa in India.

4.

Firefighters who eat better can combat cancer.

5.

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot